Genomictree

Genomictree EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Genomictree (228760.KQ) as of Nov 3, 2026 is -11.30 B KRW. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -14.75 B KRW — a change of -23.39% (higher).

EBITDA

-11.30 BKRW

YoY

-23.39%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Genomictree is 2025 -11.30 B KRW. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Genomictree was 2024 -14.75 B KRW. It decreases by -23.39% higher compared to the previous year.

The Genomictree EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2017
-1.91 B KRW
Jan 1, 2019
-12.07 B KRW
Jan 1, 2020
-11.85 B KRW
Jan 1, 2021
-9.22 B KRW
Jan 1, 2022
5.10 B KRW
Jan 1, 2023
-12.13 B KRW
Jan 1, 2024
-14.75 B KRW
Jan 1, 2025
-11.30 B KRW
The Genomictree EBITDA history
YEAREBITDAYoY
-11.30 BKRW-23.39%
-14.75 BKRW+21.59%
-12.13 BKRW-337.97%
5.10 BKRW-155.27%
-9.22 BKRW-22.19%
-11.85 BKRW-1.78%
-12.07 BKRW+532.01%
-1.91 BKRW+57.72%
-1.21 BKRW+85.90%
-651.20 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Genomictree Stock analysis

What does Genomictree do? Genomictree, Inc. generates revenue by developing and supplying diagnostic products focused on cancer screening and prognosis. The firm conducts genomic analysis using microarrays and next generation sequencing analysis, while also performing clinical trials for its molecular diagnostic products. These offerings are designed to support medical professionals in identifying and managing various oncological conditions through advanced genetic testing methodologies. The company’s product portfolio is divided into cancer molecular diagnostic products and molecular genetic diagnostic products. The cancer molecular diagnostic segment includes specific tests for colorectal cancer, bladder cancer, lung cancer, stomach cancer, and cervical cancer. This targeted approach allows the firm to address a broad spectrum of oncological needs within the diagnostic market. Within the molecular genetic diagnostic products category, Genomictree, Inc. provides epidermal growth factor receptor (EGFR) mutation diagnosis and human papilloma virus (HPV) diagnostic products. By offering these specialized genetic tests, the company serves the healthcare sector with tools necessary for precise patient diagnosis and treatment planning based on genomic data. Genomictree is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genomictree stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Genomictree is -11.30 B KRW in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Genomictree changed from -14.75 B KRW to -11.30 B KRW, representing a -23.39% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Genomictree since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Genomictree historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Genomictree

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Genomictree